Key clinical point: For patients with Crohn’s disease, complete mucosal healing on endoscopy was associated with significantly lower rates of treatment failure, intestinal resection, and hospitalization, compared with partial mucosal healing.

Major finding: Rates of treatment failure were 25% in patients with complete endoscopic healing (Crohn’s Disease Endoscopic Index of Severity scores of 0) and 48% in patients with partial endoscopic healing (CDEIS scores greater than 0 but less than 4; P = .045) .

Study details: Two-center retrospective study of 84 consecutively identified adults with clinically remitted Crohn’s disease.

Disclosures: No external funding sources were reported. Two coinvestigators disclosed ties to AbbVie, Amgen, Biogaran, Biogen, Ferring, Janssen, MSD, Pfizer, Takeda, and several other pharmaceutical companies. The remaining investigators reported having no relevant conflicts of interest.